An Di Kang Biotechnology

Andikang Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative vaccines for respiratory infectious diseases. The company's lead program is a quadrivalent live attenuated influenza vaccine (LAIV), licensed from AstraZeneca's MedImmune, which is currently in Phase 3 clinical trials in China. This nasal spray vaccine offers a needle-free alternative to traditional injectable flu shots, potentially increasing vaccination rates among children and adults. Andikang is also developing a pipeline of vaccine candidates for respiratory syncytial virus (RSV) and other viral pathogens using recombinant protein and live attenuated platforms. Backed by major investors such as Hillhouse Capital and Sequoia China, the company is building large-scale manufacturing facilities to support the commercial launch of its products. The company aims to modernize the vaccine landscape in China and address significant public health challenges through advanced biotechnology.